Novartis Suspends US Marketing and Sales of Zelnorm

Novartis Suspends US Marketing and Sales of Zelnorm

Swiss company Novartis AG said today it is complying with a request from the FDA to suspend US marketing and sales of its irritable bowel syndrome treatment Zelnorm. Novartis said it took the action after it notified the FDA about a retrospective analysis of pooled clinical trial data that shows a numerical imbalance in cardiovascular events in patients taking Zelnorm compared to those on placebo.